OrthoPediatrics Corp. Hits New 52-Week High at $25.13

OrthoPediatrics Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 25.13 on August 13, 2026. This achievement marks a notable increase from its 52-week low of USD 14.42, reflecting a substantial upward movement in the stock's performance over the past year. Despite this recent high, OrthoPediatrics Corp. has experienced a 1-year performance decline of 16.05%, contrasting sharply with the S&P 500's gain of 20.6% during the same period. The company's market capitalization stands at USD 392 million, indicating its microcap status within the industry. Financial metrics reveal a debt-to-equity ratio of 0.13, suggesting a relatively low level of debt compared to equity. However, the company is currently loss-making, as indicated by the absence of a price-to-earnings ratio. Additionally, OrthoPediatrics Corp. does not offer a dividend, and its return on equity is reported at -8.49%. The price-to-book ratio stands at 1.13, providing further insight into the company's valuation in the market.